Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007. Christopher Anzalone, its Chief Operating Officer. This carries positive implications for current and future shareholders. It is on the cusp of important breakthroughs both in products and in potential financial rewards. Firms that gain partnerships with reputable Pharma industry powerhouses set themselves up for large cash injections vital to drug development and regulatory approval phases.Īrrowhead finds itself in an excellent position against this background of factors. Such companies often take many years to become profitable.įinancial backing that is robust and recurrent is critical for success. They must also depend on a core of dedicated and talented scientists and recurrent funding for research and development. It often overlaps with related scientific fields and has expanded to include new and diverse fields such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests.īiotech companies that succeed must develop solid and systematic approaches to human disease. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing." The Biotech Spaceīiotechnology involves the use of living systems and organisms to develop products. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. "Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. A recent Arrowhead press release describes the company's mission: The company is systematically tackling drug treatments for a range of diseases based on its unified platform. Photo by metamorworks/iStock via Getty Images IntroductionĪrrowhead Pharmaceuticals ( NASDAQ: ARWR) is a promising story with more chapters to come.